Vincentage Pharma said its oral GLP-1 agonist was associated with mean weight loss of 12.4% over one year and is preparing to pursue Eli Lilly’s orforglipron route with Chinese regulatory submissions. The update positions Vincentage to compete in the fast-growing oral GLP-1 market, where efficacy and convenience are both key differentiators. The company’s next steps will depend on how regulators evaluate the balance of weight-loss magnitude, tolerability, and long-term outcomes data. Competitive pressure is also likely given the pace of GLP-1 development efforts globally. If Vincentage can establish a robust clinical and regulatory package, the program could strengthen the presence of oral incretin therapies in China’s obesity treatment landscape.